Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.

Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.

PURPOSE Ribonucleotide reductase (RR) is a therapeutic target for DNA replication-dependent diseases such as cancer. Here, a potent small interfering RNA (siRNA) duplex against the M2 subunit of RR (RRM2) is developed and shown to reduce the growth potential of cancer cells both in vitro and in vivo. EXPERIMENTAL DESIGN Three anti-RRM2 siRNAs were identified via computational methods, and the...

Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.

PURPOSE Previous gene transfection studies have shown that the accumulation of human ribonucleotide reductase small subunit M2 (hRRM2) enhances cellular transformation, tumorigenesis, and malignancy potential. The latest identified small subunit p53R2 has 80% homology to hRRM2. Here, we investigate the role of p53R2 in cancer invasion and metastasis. EXPERIMENTAL DESIGN The immunohistochemist...

An analysis of human equilibrative nucleoside transporter-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: Implications for adjuvant treatment

Ribonucleotide reductase small subunit M2 expression and its clinical significance in lung adenocarcinoma tissues

Lung cancer is one of the most lethal cancers worldwide. At present, cancer cells metastasis becomes the hot spot. Related studies showed that ribonucleotide reductase small subunit M2 (RRM2) is associated with tumor cell invasion, metastasis, and angiogenesis. It can activate a series of proto-oncogenes to promote tumor growth. This study investigates RRM2 expression and clinical significance ...

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

The results of administering escalating, i.v. doses of targeted nanoparticles containing a siRNA targeting the M2 subunit of ribonucleotide reductase to non-human primates are reported. The nanoparticles consist of a synthetic delivery system that uses a linear, cyclodextrin-containing polycation, transferrin (Tf) protein targeting ligand, and siRNA. When administered to cynomolgus monkeys at d...